NTLA is trading approximately 4.9% up at $16.00 as investors selectively buy back into gene-editing names following a period of sector volatility.
- The move follows a sharp pullback tied to risk-off sentiment in high-beta biotech and tech, with no fresh company-specific news reported this morning.
- Broader markets are stabilizing, and investors appear to be refocusing on the company's intact regulatory and pipeline progress.